Communications publiées lors de congrès ou colloques nationaux et internationaux (23)
3.
Piccart-Gebhart, M., Cardoso, F., Di Leo, A., Awada, A., & Gelber, R. (2002). Controversies in adjuvant systemic therapy of breast cancer. Part I: areas of controversy in the adjuvant systemic therapy of endocrine non-responsive breast cancer. ASCO Educational Book (pp. 144-155) ASCO's annual meeting(May 18-21, 2002: Orlando).4.
Awada, A., Hendlisz, A., Gil, T., Munoz Bermeo, R. A., Bartholomeus, S., de Valeriola, D., van der Auwera, J., Coppieters, S., Moeller, J., & Piccart-Gebhart, M. (2002). Final results of a clinical and pharmacokinetic (PK) phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: A promising anti-tumor agent. European Journal of Cancer. Vol. 38 (p. 52) (2002).5.
Awada, A., Dubuisson, M., Sales, F., Vereecken, P., Gil, T., Cutler, D. L., Moerman, C., Branle, F., Lehmann, F., Klastersky, J., de Valeriola, D., & Piccart-Gebhart, M. (2002). A phase I study of a prolonged schedule of temozolimide (Temodal (R)) plus liposomal doxorubicin (Caelyx (R)) in advanced solid cancers: Final results of a promising combination. Proceedings of the American Society of Clinical Oncology. Vol. 21 (p. 79) (2001).6.
Awada, A., Hendlisz, A., Gil, T., Bleiberg, H., Bartholomeus, S., de Valeriola, D., Dewitte, M., Coppieters, S., Moeller, J., De Becker, D., Meert, A.-P., & Piccart-Gebhart, M. (2001). A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors. AACR-NCI-EORTC. Vol. 7 (p. 3768) (October 29 - November 2, 2001: Miami).7.
Hennebert, P., Biganzoli, L., Van Hoorebeeck, I., Awada, A., Coleman, R., Piccart-Gebhart, M., de Valeriola, D., et al. (2001). Pharmacokinetic phase I study of Caelyx in metastatic breast cancer patients. Proceedings of the Pharmacology and Molecular Mechanisms Group Winter Meeting of the EORTC (Janvier 2001: Verona, Italy)8.
Awada, A., Burris, H. H., de Valeriola, D., Hendlisz, A., Huart, A., Gil, T., Crabeels, D., Moerman, C., Piccart-Gebhart, M., et al. (2001). Phase I clinical and pharmacology study of the novel epothilone analog BMS-247550 given weekly in patients advanced solid tumors. Clinical for Cancer Research. Vol. 7 (p. 3810) (2001).9.
Awada, A., Bleiberg, H., de Valeriola, D., Huart, A., Cornez, N., Piccart-Gebhart, M., et al. (2001). Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (pts) with advanced solid tumors. Proceedings of the American Society of Clinical Oncology. Vol. 20 (p. 108) (2001).10.
Bourgeois, P., Awada, A., Cornez, N., Mccabe, S., Gil, T., Branle, F., de Valeriola, D., Di Leo, A., Palmer, P., Piccart-Gebhart, M., & Fruhling, J. (2000). 99mTc-MIBI scintigraphies for the pharmacodynamic evaluation of R101933: A new inhibitor of the MDR-1 P-glycoprotein (PgP). Eur J Nucl Med. Vol. 27 (p. 8) (2000).11.
Awada, A., Bleiberg, H., Gil, T., Di Leo, A., Geurs, F., de Valeriola, D., Mc Cabe, S., Palmer, P., Woestenborghs, R., Piccart-Gebhart, M., et al. (1999). Oral R101933, an inhibitor of MDR1 P-glyco-protein does not significantly after the pharmacokinetics and pharmacodynamics of Paclitaxel. Proceedings of the American Association for Cancer Research. Vol. 40 (p. 663) (1999).12.
Awada, A., Bourgeois, P., Cornez, N., Bleiberg, H., Mccabe, S., Gil, T., Lehmann, F., de Valeriola, D., Di Leo, A., Piccart-Gebhart, M., et al. (1999). A clinical pharmacodynamic (Pd) and pharmacokinetic (Pk) phase I study of I.V. R101933, an inhibitor of MDR1 P-glycoprotein (PgP) given alone and in combination with Taxol in patients with solid tumors. Clinical Cancer Research. Vol. 5 (p. 3833) (1999).13.
de Valeriola, D., Awada, A., Van Vreckem, A., Habboubi, N., Riva, A., & Piccart-Gebhart, M. (1998). Influence of amifostine (A) on the toxicity and pharmacokinetics (PK) of docetaxel (D) in breast cancer patients: An EORTC-IDBBC study. European Journal of Cancer 1st European Breast Cancer Conference(Septembre 1998: Florence, Italy)14.
Awada, A., de Valeriola, D., Gil, T., Kerger, J., Selleslags, J., Van Vreckem, A., Brassine, C., Hennebert, P., Riva, A., Piccart-Gebhart, M., et al. (1998). Influence of the cytoprotective agent Amifostine on toxicity and pharmacokinetics (PK) of Docetaxel (D) in metastasic breast cancer (MBC): A feasibility study of the EORTC-Investigational Drug Branch for Breast Cancer. Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Vol. 55 (Juin 1998: Amsterdam, The Nederlands).